Immunocore Holdings plc(IMCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMCR Immunocore Holdings plc

Trading 10-20 11:54:39 EDT

31.59

+1.75

+5.86%

High31.79	Low30.11	Vol196.71K
Open30.11	D1 Closing29.84	Amplitude5.63%
Mkt Cap1.63B	Tradable Cap1.45B	Total Shares51.50M
T/O6.18M	T/O Rate0.43%	Tradable Shares45.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMCR","market":"US","secType":"STK","nameCN":"Immunocore Holdings plc","latestPrice":31.59,"timestamp":1792511646283,"preClose":29.84,"halted":0,"volume":196711,"delay":0,"changeRate":0.05864611260053619,"floatShares":45834900,"shares":51498617,"eps":-0.356599,"marketStatus":"Trading","change":1.75,"latestTime":"10-20 11:54:39 EDT","open":30.11,"high":31.79,"low":30.11,"amount":6182483.130969999,"amplitude":0.0563,"askPrice":31.77,"askSize":60,"bidPrice":31.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.356599,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792526400000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":29.84,"preHourTrading":{"tag":"盘前","latestPrice":30.1,"preClose":29.84,"latestTime":"09:29 EDT","volume":300,"amount":9028.0002,"timestamp":1792502999984,"change":0.26,"changeRate":0.008713,"amplitude":0.000335},"postHourTrading":{"tag":"盘后","latestPrice":29.84,"preClose":29.84,"latestTime":"19:11 EDT","volume":12483,"amount":372493.97,"timestamp":1792451468137,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.889824,"impliedVol":0.5099,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/IMCR/tweets","defaultTab":"tweets","newsList":[{"id":"2675584213","title":"Immunocore Doses First Patient in Phase 1 Trial of Type 1 Diabetes Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2675584213","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675584213?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:15","pubTimestamp":1792066542,"startTime":"0","endTime":"0","summary":"Immunocore  said Thursday it dosed the first patient in a Phase 1 trial of IMC-S118AI, an investigational therapy for type 1 diabetes.The bispecific molecule is designed to selectively suppress immune attacks on insulin-producing pancreatic beta cells, it said.Immunocore said the trial will evaluate safety, pharmacokinetics and clinical activity in patients with the HLA-A*02:01 genetic marker.The candidate aims to preserve beta cells and insulin production, it added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMCR","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675586456","title":"Immunocore Announces First Patient Dosed in the Phase 1 Trial of Imc-S118ai – Its First Tissue-Specific Autoimmune Candidate – for Patients with Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2675586456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675586456?lang=en_us&edition=fundamental","pubTime":"2026-10-15 19:00","pubTimestamp":1792062000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261015:nTUA1XN8YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMCR","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653336","title":"Immunocore Completes Enrollment in Phase 3 Melanoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653336","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653336?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:50","pubTimestamp":1789386615,"startTime":"0","endTime":"0","summary":"An announcement from Immunocore Holdings ( ($IMCR) ) is now available. On September 14, 2026, Immunocore announced it had reached target enrollment...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunocore-completes-enrollment-in-phase-3-melanoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunocore-completes-enrollment-in-phase-3-melanoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668170","title":"Immunocore achieves target patient enrollment in TEBE-AM clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668170?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:20","pubTimestamp":1789384814,"startTime":"0","endTime":"0","summary":"Immunocore (IMCR) announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patien...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-achieves-target-patient-enrollment-in-tebe-am-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4505","IMCR","HYLG","BK4139","IDNA","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668352","title":"Immunocore - Achieves Target Enrollment in Tebe-am Trial with Kimmtrak in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668352?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:05","pubTimestamp":1789383949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN455028:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMCR","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667359668","title":"Immunocore - Topline Overall Survival Data from Tebe-am Trial Expected by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667359668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667359668?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:05","pubTimestamp":1789383949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN455028:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMCR","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066881","title":"Immunocore Reaches 540-Patient Enrollment Target in Phase 3 TEBE-am Trial of Kimmtrak in Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066881?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:03","pubTimestamp":1789383837,"startTime":"0","endTime":"0","summary":"Immunocore reaches 540-patient enrollment target in Phase 3 TEBE-AM trial of Kimmtrak in advanced melanomaImmunocore reached target enrollment of 540 patients in the Phase 3 TEBE-AM trial of KIMMTRAK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDLcfZhnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885376","title":"Immunocore to Present at Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885376","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664885376?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:04","pubTimestamp":1788260677,"startTime":"0","endTime":"0","summary":"Immunocore to present at Cantor Global Healthcare Conference fireside chatImmunocore management will appear at investor conferences in mid-September 2026, starting with a fireside chat on Sept. 10.Additional fireside chats are scheduled for Sept. 14 and Sept. 15.The company also plans 1x1 and small-group investor meetings on Sept. 16.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL2M5wsF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMCR","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661292426","title":"Immunocore Holdings Price Target Announced at $50.00/Share by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661292426","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661292426?lang=en_us&edition=fundamental","pubTime":"2026-08-22 03:17","pubTimestamp":1787339820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMCR/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMCR","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660437147","title":"Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660437147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660437147?lang=en_us&edition=fundamental","pubTime":"2026-08-18 05:25","pubTimestamp":1787001921,"startTime":"0","endTime":"0","summary":"Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period.\nSee our latest analysis for Immunocore Holdings.\nAt a share price of US$34.21, Immunocore Holdings shows a 90 day share price return of 18.25%, while the 1 year total shareholder return of 5.88% contrasts with a 3 year total shareholder return that is down 42.85%. This suggests that momentum has been rebuilding...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657418356","title":"Immunocore price target raised to $43 from $40 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657418356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657418356?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:40","pubTimestamp":1786110056,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Immunocore (IMCR) to $43 from $40 and keeps an Equal Weight rating on the shares. Published first ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunocore-price-target-raised-to-43-from-40-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunocore-price-target-raised-to-43-from-40-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645754","title":"Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Immunocore Holdings (IMCR) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645754?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:40","pubTimestamp":1786106428,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS), Immunocore Holdings (IMCR) and Pra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE0009355771.USD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4581","IE00B2B36J28.USD","IMCR","LU1839511570.USD","IE00BJJMRZ35.SGD","BK4137","BK4585","XLV","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","VTRS","HCSG","LABU","IE00BFTCPJ56.SGD","IBRN","BK4583","LU0128526141.USD","PRAX","BK4505","IE0002141913.USD","LU2087621335.USD","BK4588","BK4007","XBI","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699655","title":"Analysts Are Bullish on These Healthcare Stocks: Immunocore Holdings (IMCR), Natera (NTRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699655?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:20","pubTimestamp":1786080009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunocore Holdings (IMCR) and Natera (NTRA) with bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-immunocore-holdings-imcr-natera-ntra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","NTRA","LU2065171402.SGD","LU2065170008.USD","GNOM","LU0345770993.USD","LU2065731478.USD","LU2065171311.SGD","LU1064131342.USD","IMCR","BK4505","LU0345770308.USD","LU2324357040.USD","LU0106261612.USD","LU0963586101.USD","LU2264538146.SGD","LU0053671581.USD","LU1988902786.USD","HELX","LU0012050646.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657537356","title":"Needham Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657537356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657537356?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:35","pubTimestamp":1786030540,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Immunocore Holdings today and set a price target of $75.00. According to TipRanks, Blum is a 5-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-immunocore-holdings-imcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-immunocore-holdings-imcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632494","title":"Immunocore Holdings PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632494","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632494?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023175,"startTime":"0","endTime":"0","summary":"Immunocore Holdings PLC reports results for the quarter ended June 30 - Earnings SummaryImmunocore Holdings PLCIMCR.OQreported a quarterly adjusted loss of 2 cents per share for the quarter ended June","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639952","title":"Immunocore Publishes Corporate Presentation on Bispecific Soluble TCR Platform and Pipeline Across Oncology, Infectious and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639952?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:15","pubTimestamp":1786018523,"startTime":"0","endTime":"0","summary":"Immunocore publishes corporate presentation on bispecific soluble TCR platform and pipeline across oncology, infectious and autoimmune diseasesImmunocore highlighted KIMMTRAK as the standard of care i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL2qC4Qg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363361","title":"Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363361?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015333,"startTime":"0","endTime":"0","summary":"Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638746","title":"UK's Immunocore Q2 EPS Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638746","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638746?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:14","pubTimestamp":1786014856,"startTime":"0","endTime":"0","summary":"UK's Immunocore Q2 EPS misses estimatesOverviewUK biotech firm's Q2 KIMMTRAK revenue rose 18% yr/yr, driven by higher US and global salesQ2 adjusted EPS and net income missed analyst expectations; ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430HB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4007","CHRS","EYPT","LU0320765992.SGD","BK4588","IMCR","LU0109394709.USD","BK4505","BK4535","LU0889565916.HKD","HIK.UK","IE00B0JY6N72.USD","BK5011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638220","title":"Immunocore Q2 FY26 Net Loss Narrows to $0.8 Million; Revenue Rises 18% to $115.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638220","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638220?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:12","pubTimestamp":1786014744,"startTime":"0","endTime":"0","summary":"Immunocore Q2 FY26 net loss narrows to $0.8 million; revenue rises 18% to $115.9 millionImmunocore posted Q2 net sales of $115.9 million, up 18% year over year, driven by higher volumes in the US and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL6RCk2d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IMCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638619","title":"Immunocore Hldgs Q2 EPS $(0.02) Misses $0.02 Estimate, Sales $115.927M Beat $110.374M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638619","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638619?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:05","pubTimestamp":1786014328,"startTime":"0","endTime":"0","summary":"Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 90 percent increase over losses of $(0.20) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60987550/immunocore-hldgs-q2-eps-0-02-misses-0-02-estimate-sales-115-927m-beat-110-374m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMCR","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunocore.com","stockEarnings":[{"period":"1week","weight":0.0275},{"period":"1month","weight":-0.0675},{"period":"3month","weight":-0.1346},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.1108},{"period":"ytd","weight":-0.1403}],"compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0243},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.1537},{"period":"ytd","weight":0.124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.031356},{"month":2,"riseRate":0,"avgChangeRate":-0.062034},{"month":3,"riseRate":0.333333,"avgChangeRate":0.007534},{"month":4,"riseRate":0.5,"avgChangeRate":0.010332},{"month":5,"riseRate":0.5,"avgChangeRate":-0.014019},{"month":6,"riseRate":0.5,"avgChangeRate":0.000567},{"month":7,"riseRate":0.833333,"avgChangeRate":0.07593},{"month":8,"riseRate":0.5,"avgChangeRate":0.002477},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.047839},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.000295},{"month":11,"riseRate":0.8,"avgChangeRate":0.095366},{"month":12,"riseRate":0.2,"avgChangeRate":-0.012917}],"exchange":"NASDAQ","name":"Immunocore Holdings plc","nameEN":"Immunocore Holdings plc","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunocore Holdings plc(IMCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunocore Holdings plc(IMCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunocore Holdings plc,IMCR,Immunocore Holdings plc股票,Immunocore Holdings plc股票老虎,Immunocore Holdings plc股票老虎国际,Immunocore Holdings plc行情,Immunocore Holdings plc股票行情,Immunocore Holdings plc股价,Immunocore Holdings plc股市,Immunocore Holdings plc股票价格,Immunocore Holdings plc股票交易,Immunocore Holdings plc股票购买,Immunocore Holdings plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunocore Holdings plc(IMCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunocore Holdings plc(IMCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction